Betaseron injection for relapsing forms of multiple sclerosis in adults

Betaseron is an injectable medicine containing interferon beta-1b used to treat adults with relapsing forms of multiple sclerosis (MS). It helps manage clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS by modifying the disease course.

Betaseron is prescribed for adults with relapsing forms of multiple sclerosis, including:

• Clinically isolated syndrome (a first neurological episode suggestive of MS)
• Relapsing-remitting MS
• Active secondary progressive MS

interferon beta-1b

Betaseron contains interferon beta-1b, a protein that modulates the body's immune response. It works by reducing inflammation and altering immune system activity that contributes to nerve damage in multiple sclerosis, thereby helping to slow disease progression.

Dosage and Administration

Betaseron is given by subcutaneous injection every other day. The usual maintenance dose is 0.25 mg (1 mL) every other day, but dosing starts lower and is gradually increased over six weeks as follows:

Missed doses should be taken as soon as possible unless it is near the time of the next scheduled dose. Do not take doses on two consecutive days. If overdosing or two consecutive doses occur, contact a healthcare provider immediately.

Reconstitution Instructions

• Only use vials that are intact and undamaged.
• Attach the prefilled syringe with diluent to the BETASERON vial using the vial adapter.
• Inject 1.2 mL diluent slowly into the vial and gently swirl to dissolve the powder; do not shake.
• Allow foam to settle before withdrawing.
• 1 mL of reconstituted solution contains 0.25 mg interferon beta-1b.
• Use immediately or refrigerate (2°C to 8°C) and use within 3 hours; do not freeze.

Administration

• Inject subcutaneously using supplied syringes or the BETACONNECT autoinjector with guidance on injection depth.
• First injection should be supervised by a healthcare professional.
• Patients with severe neurological impairment should have assistance with injections.
• Rotate injection sites to reduce risk of severe skin reactions.

Symptom Management

Use analgesics or antipyretics on injection days to help reduce flu-like symptoms often experienced with Betaseron.

Betaseron is contraindicated in patients with known hypersensitivity to natural or recombinant interferon beta, human albumin, mannitol, or any other component of the formulation.

Important Warnings and Precautions

• Hepatic injury: Monitor liver function tests; discontinue if severe liver damage occurs.
• Anaphylaxis and allergic reactions: Discontinue immediately if anaphylaxis or serious allergic symptoms occur.
• Depression and suicide: Advise patients to report depression or suicidal thoughts promptly; consider stopping treatment if these develop.
• Congestive heart failure (CHF): Monitor patients with CHF closely; discontinue if condition worsens without other causes.
• Injection site reactions: Severe reactions including necrosis can occur; avoid injecting into affected areas until healed, rotate sites, and discontinue if multiple lesions develop.
• Leukopenia: Monitor complete blood counts regularly; dose reduction may be necessary.
• Thrombotic microangiopathy (TMA): Rare but serious blood disorders have been reported; discontinue if suspected.
• Pulmonary arterial hypertension (PAH): Cases reported, sometimes requiring hospitalization. Evaluate unexplained dyspnea or fatigue; discontinue if PAH confirmed.
• Flu-like symptoms: Common, especially early in treatment; may improve with analgesics/antipyretics.
• Drug-induced lupus erythematosus: Discontinue if new symptoms suggest this condition.

Common and Serious Side Effects

• Injection site reactions: Occur in about 78% of patients; include pain, inflammation, hypersensitivity, and in 4% injection site necrosis.
• Flu-like symptoms: Seen in about 57% of patients initially, usually decreasing over time.
• Leukopenia: Reported in approximately 18% of treated patients.
• Depression and suicidal ideation: Occurred more frequently compared to placebo.
• Allergic reactions: Including rare anaphylaxis, dyspnea, bronchospasm, skin rash.
• Thrombotic microangiopathy and pulmonary arterial hypertension: Rare but serious.

No specific drug interaction adjustments outlined in the label; consider potential additive hepatotoxicity with other liver-affecting drugs or alcohol.

If a patient accidentally takes more than prescribed or administers injections on two consecutive days, contact their healthcare provider immediately. No further specific overdose management details are provided.

• Store lyophilized powder as directed (no specific temperature given in excerpt).
• Reconstituted solution: refrigerate at 2°C to 8°C (35°F to 46°F) if not used immediately, and use within 3 hours.
• Do not freeze reconstituted Betaseron solution.